Table 2.

Mouse survival study. Compounds were delivered by intravenous tail vein injection (i.v.) or intraperitoneal injection (i.p.).

Compound	Treatmenta	N	Percent Surviving
BH4
	2 mg – i.v.	3	33
	10 mg – i.p.	1	100
TAT
	2 mg – i.v.	6	0
	2 mg – i.p.	10	100
	5 mg – i.p.	2	0
TAT-BH4
	2 mg – i.v.	7	14
	2 mg – i.p.	4	100
	5 mg – i.p.	4	75
	20 mg – i.p	4	25
NLS
	2 mg – i.v.	6	100
NLS-BH4
	2 mg – i.v.	6	100
	2 mg – i.p.	3	100
	10 mg – i.p.	3	100
	30 mg – i.p.	3	100

^aIntravenous injections were performed in C57Bl/6J mice. Intraperitoneal injections were performed in both C57Bl/6J and CD1 mice. Results were similar for both strains and data from the CD1 mice is presented.